

## SYNTHESIS AND MOLECULAR DOCKING STUDY OF 2-ARYL/HETEROARYL-6-CHLOROQUINOLINE-4-CARBOXYLIC ACIDS WITH PLASMODIUM LDH RECEPTOR PROTEIN

T. O. SHRUNGESH KUMAR<sup>1</sup>, K. M. MAHADEVAN<sup>1\*</sup>, P. S. SUJAN GANAPATHY<sup>2</sup>, M. N. KUMARA<sup>3</sup>

<sup>1</sup>Department of Post Graduate Studies and Research in Chemistry, School of Chemical Science, Kuvempu University, Shankaraghatta, Karnataka, 577451, India, <sup>2</sup>Centre for Advanced Studies in Biosciences, Jain University, Bangalore 560024, India, <sup>3</sup>Department of Chemistry, Yuvaraja's College, University of Mysore, Mysore-570005, Karnataka, India.  
Email: mahadevan.kmm@gmail.com

Received: 11 Aug 2014 Revised and Accepted: 15 Sep 2014

### ABSTRACT

**Objective:** Synthesis and *in silico* molecular docking studies of 2-aryl/heteroaryl-quinoline-4-carboxylic acid derivatives (**3a-j**) with plasmodium LDH receptor protein.

**Methods:** The 2-aryl/heteroaryl-quinoline-4-carboxylic acids (**3a-j**) were obtained by Pfitzinger reaction. Ligands (**3a-j**) interaction with plasmodium LDH receptor protein was studied through molecular docking method.

**Results:** Good yields of 2-aryl/heteroaryl-quinoline-4-carboxylic acid derivatives (**3a-j**) were obtained by convenient and economical procedure. Their structures were confirmed by <sup>1</sup>H NMR, <sup>13</sup>C NMR, and MS spectral analysis. The binding site analysis of the synthesized compounds (**3a-j**) with plasmodium LDH receptor that are responsible for malaria parasite response was evaluated through molecular docking study. The results reveal that the ligand **3d** shows maximum of five hydrogen bonding interactions with binding energy -9.05 kcal/mol, shown to be a promising lead molecule to inhibit Plasmodium LDH receptor.

**Conclusion:** The docking studies of newly synthesized 2-aryl/heteroaryl-quinoline-4-carboxylic acids were found to be very useful ligands for antimalarial therapy particularly on Plasmodium LDH protein. However the installation of still many appropriate substitutions on quinoline moiety would lead to identification of novel antimalarial compounds that ascertained *via* molecular docking is underway in our lab.

**Keywords:** Pfitzinger synthesis, 2-aryl/heteroaryl-quinoline-4-carboxylic acids, Molecular docking, Lactate dehydrogenase (LDH), Antimalarial.

### INTRODUCTION

Diversely substituted quinolines are found to be valuable compounds and find wider applications in pharmaceutical field [1]. Most important use of the quinoline ring is its antimalarial potential. For example, the mefloquine and talnetant [2] are some important substituted quinoline nucleuses (**Fig. 1**) as antimalarial drugs. There are many 7-chloroquinolines [3, 4], and analogues of ferrochloroquine [5] are also exhibited good degree of antimalarial activity against both chloroquine-resistant and chloroquine-sensitive parasites. Certain, 7-chloroquinolinyl thioureas [6] are also reported as potential antimalarial agents.





Fig. 1

Hence, due to their importance a number of methods for the synthesis of quinolines have been developed [7-10]. The syntheses of 2-aryl/heteroaryl-quinoline-4-carboxylic acids are normally obtained by Pfitzinger synthesis. Besides, there are some classic condensation-type approaches, includes Skraup, Doebner-von Miller, Friedlander, and Combes reactions [11,12] are also known. Although, 6-chloroquinolines are also potential lead compounds for

antimalarial property (**Fig. 2**) [13] there are no much reports on such molecules. Hence, in this report we studied the possibility for their synthesis to generate structurally distinct 6-chloroquinolines by very simple and convenient method and studied their binding interaction with malaria parasite as preliminary study.



Hence, keeping in view of biological activities exhibited by chloroquinolines and in continuation of our effort to identify new quinoline based therapeutic agents[14-25], in the present investigation we report one pot Pfitzinger synthesis of some novel 2-aryl/heteroaryl-6-chloroquinoline-4-carboxylic acids (**3a-j**) by using 5-chloroisatin and various substituted acetophenones and acetyl heterocyclic compounds with 33% potassium hydroxide solution.

We also performed molecular docking studies in order to understand how various 2-aryl/heteroaryl-6-chloroquinoline-4-carboxylic acids interact with Lactate dehydrogenase and to explain the differences in their activity. The characterization data of various

2-aryl/heteroaryl-6-chloroquinoline-4-carboxylic acids are presented in the experimental section.

## MATERIALS AND METHODS

### Chemistry

The TLC was performed on alumina silica gel 60 F254 (Merck). The mobile phase was hexane and ethyl acetate (7:3 v/v) and detection was made using UV light (254 nm). Melting points of the synthesized compounds were determined by electrothermal apparatus in open capillaries and are uncorrected. The <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra recorded on Bruker (Bangalore, India) AM 400 (at 400 and 100 MHz, respectively) model spectrophotometer in CDCl<sub>3</sub> or DMSO-*d*<sub>6</sub> as solvent. Chemical shifts are expressed as  $\delta$  values relative to TMS as internal standard. Mass spectra were recorded on a Jeol SX 102=DA-6000(10 kV) FAB mass spectrometer.

### Typical procedure for the synthesis of 6-chloro-2-(furan-2-yl)quinoline-4-carboxylic acid (3a)

To a solution of 5-chloroisatin 1.0 g (0.006 mol) in 33% aqueous potassium hydroxide solution (15 mL) the 1-(furan-2-yl) ethanone 0.6 g (0.006 mol) was added, and the mixture was heated under reflux for 14-16 hr. The completion of the reaction was monitored by thin layer chromatography [hexane and ethyl acetate (7:3 v/v)]. The reaction mixture was poured into a crushed ice (100 mL) and acidified to pH 1 with 1 M aqueous hydrochloric acid. The precipitate was collected by filtration, washed with water, and dried under vacuum to afford crude product.

The crude product was purified by column chromatography with silica gel (60-120 mesh, petroleum ether: ethyl acetate, 7:3 v/v) furnished analytically pure compound **3a**, yield 80%. Similarly, all other derivatives (**3b-j**) were obtained.

### Spectral data

#### 6-chloro-2-(furan-2-yl) quinoline-4-carboxylic acid (3a)

Elution from silica using 30% ethyl acetate in hexanes afforded the title compound as a yellow solid.<sup>1</sup>H-NMR (400 MHz, DMSO-*d*<sub>6</sub>):  $\delta$ =13.16 (s, 1H), 8.98 (s, 1H), 8.59 (s, 1H), 8.23 (d, *J*=2.40 Hz, 1H), 7.87 (d, *J*=2.40 Hz, 1H), 7.45 (d, *J*=3.20 Hz, 1H), 6.75-6.76 (m, 1H), 6.35-6.36 (m, 1H) ppm.<sup>13</sup>C-NMR (100 MHz, DMSO-*d*<sub>6</sub>)  $\delta$ =10.23, 13.78, 91.85, 97.95, 112.53, 113.04, 113.47, 117.68, 120.58, 125.08, 127.06, 135.95, 141.59, 144.17, 145.90, 159.43 ppm. MS. *m/z* =273.95 (M<sup>+</sup>).

#### 6-chloro-2-(5-methylfuran-2-yl) quinoline-4-carboxylic acid (3b)

Elution from silica using 30% ethyl acetate in hexanes afforded the title compound as a pale yellow solid.<sup>1</sup>H-NMR (400 MHz, DMSO-*d*<sub>6</sub>):  $\delta$ =14.01 (s, 1H), 9.05 (s, 1H), 8.59 (s, 1H), 8.25 (d, *J*=2.40 Hz, 1H), 7.87 (d, *J*=2.40 Hz, 1H), 6.2 (*J*=3.20 Hz, 1H), 5.8-5.9 (m, 1H), 1.45 (s, 3H) ppm.<sup>13</sup>C-NMR (100 MHz, DMSO-*d*<sub>6</sub>)  $\delta$ =13.58, 109.29, 113.16, 119.16, 123.87, 124.40, 130.66, 131.16, 131.75, 135.73, 146.95, 148.42, 150.57, 155.10, 159.76 ppm. MS. *m/z* =287.88 (M<sup>+</sup>).

#### 6-chloro-2-(1-methyl-1H-pyrrol-2-yl)quinoline-4-carboxylic acid (3c)

Elution from silica using 30% ethyl acetate in hexanes afforded the title compound as a brown solid.<sup>1</sup>H-NMR (400 MHz, DMSO-*d*<sub>6</sub>):  $\delta$ =13.79 (s, 1H), 9.87 (s, 1H), 8.54 (s, 1H), 8.25 (d, *J*=7.60 Hz, 1H), 7.49 (dd, *J*=1.60, 8.60 Hz, 1H), 5.23 (d, *J*=8.40 Hz, 1H), 5.09-5.11 (m, 1H), 3.53 (s, 3H), 2.45 (s, 3H) ppm. <sup>13</sup>C-NMR (100 MHz, DMSO-*d*<sub>6</sub>)  $\delta$ =11.63, 13.75, 16.64, 97.18, 100.72, 100.75, 112.54, 113.06, 113.49, 117.65, 118.08, 120.58, 125.08, 127.03, 135.97, 136.56, 159.47 ppm. MS. *m/z* =300.03 (M<sup>+</sup>).

#### 2-(4-bromophenyl)-6-chloroquinoline-4-carboxylic acid (3d)

Elution from silica using 30% ethyl acetate in hexanes afforded the title compound as a pale yellow solid.<sup>1</sup>H-NMR (400 MHz, DMSO-*d*<sub>6</sub>):  $\delta$ =14.17 (s, 1H), 9.77 (s, 1H), 8.59 (s, 1H), 8.21 (d, *J*=2.40 Hz, 2H), 8.18 (d, *J*=8.80 Hz, 1H), 7.88 (d, *J*=2.40 Hz, 1H), 7.77 (d, *J*=2.80 Hz, 2H) ppm.<sup>13</sup>C-NMR (100 MHz, DMSO-*d*<sub>6</sub>)  $\delta$ =13.78, 120.24, 123.98,

129.19, 130.73, 131.75, 132.57, 136.56, 146.82, 150.10, 159.90 ppm. MS. *m/z* =361.80 (M<sup>+</sup>).

#### 6-chloro-2-[(E)-2-phenylethenyl]quinoline-4-carboxylic acid (3e)

Elution from silica using 30% ethyl acetate in hexanes afforded the title compound as a pale yellow solid.<sup>1</sup>H-NMR (400 MHz, DMSO-*d*<sub>6</sub>):  $\delta$ =14.58 (s, 1H), 9.43 (s, 1H), 8.52 (s, 1H), 8.17 (d, *J*=9.20 Hz, 1H), 7.81 (d, *J*=2.40 Hz, 1H), 7.75-7.77 (m, 3H), 7.55 (d, *J*=16.40 Hz, 1H), 7.43 (t, *J*=7.60 Hz, 2H), 7.34-7.35 (m, 1H) ppm.<sup>13</sup>C-NMR (100 MHz, DMSO-*d*<sub>6</sub>):  $\delta$ =13.59, 122.10, 124.28, 124.37, 125.98, 127.45, 127.60, 128.34, 128.84, 128.99, 130.49, 131.33, 135.30, 135.50, 135.92, 147.01, 150.89, 159.03 ppm. MS. *m/z* =309.90 (M<sup>+</sup>).

#### 6-chloro-2-[(E)-2-(4-chlorophenyl)ethenyl]quinoline-4-carboxylic acid (3f)

Elution from silica using 30% ethyl acetate in hexanes afforded the title compound as a pale yellow solid.<sup>1</sup>H-NMR (400 MHz, DMSO-*d*<sub>6</sub>):  $\delta$ =14.27 (s, 1H), 9.38 (s, 1H), 8.48 (s, 1H), 8.27 (d, *J*=9.20 Hz, 1H), 7.87 (d, *J*=2.40 Hz, 1H), 7.75-7.77 (m, 1H), 7.35-7.36 (m, 2H), 7.23-7.26 (m, 2H), 7.20-7.21 (m, 1H) ppm.<sup>13</sup>C-NMR (100 MHz, DMSO-*d*<sub>6</sub>)  $\delta$ =13.87, 104.98, 113.04, 115.03, 117.14, 117.65, 117.83, 117.85, 118.84, 118.89, 120.78, 123.34, 123.38, 123.53, 126.87, 123.96, 135.58, 143.13, 159.48, ppm. MS. *m/z* =345.95 (M<sup>+</sup>).

#### 6-chloro-2-(2,4,5-trimethoxyphenyl)quinoline-4-carboxylic acid (3g)

Elution from silica using 30% ethyl acetate in hexanes afforded the title compound as a pale yellow solid.<sup>1</sup>H-NMR (400 MHz, DMSO-*d*<sub>6</sub>):  $\delta$ =13.89 (s, 1H), 9.75 (s, 1H), 8.55 (s, 1H), 8.03 (d, *J*=9.20 Hz, 1H), 7.70 (d, *J*=2.00 Hz, 1H), 7.57 (s, 1H), 6.77 (s, 1H), 3.79-3.87 (m, 9H) ppm. <sup>13</sup>C-NMR (100 MHz, DMSO-*d*<sub>6</sub>):  $\delta$ =13.23, 55.77, 56.10, 56.50, 98.28, 114.11, 118.20, 128.87, 123.73, 124.22, 125.24, 129.87, 131.48, 133.74, 143.15, 146.86, 151.50, 152.48, 150.84, 159.25 ppm. MS. *m/z* =373.91 (M<sup>+</sup>).

#### 6-chloro-2-(naphthalen-2-yl)quinoline-4-carboxylic acid (3h)

Elution from silica using 30% ethyl acetate in hexanes afforded the title compound as a pale yellow solid.<sup>1</sup>H-NMR (400 MHz, DMSO-*d*<sub>6</sub>):  $\delta$ =14.05 (s, 1H), 9.80 (s, 1H), 8.35 (s, 1H), 8.16 (d, *J*=9.20 Hz, 1H), 7.83 (d, *J*=2.00 Hz, 1H), 7.87-7.88 (m, 3H), 7.43 (dd, *J*=3.20, 6.60 Hz, 1H), 7.30-7.31 (m, 3H) ppm.<sup>13</sup>C-NMR (100 MHz, DMSO-*d*<sub>6</sub>):  $\delta$ =13.85, 106.75, 108.89, 112.56, 113.02, 113.47, 113.98, 116.65, 116.87, 117.65, 118.05, 118.76, 119.54, 120.34, 123.71, 125.04, 135.98, 142.98, 148.10, 159.47 ppm. MS. *m/z* =333.99 (M<sup>+</sup>).

#### 6-chloro-2-(1-hydroxynaphthalen-2-yl)quinoline-4-carboxylic acid (3i)

Elution from silica using 30% ethyl acetate in hexanes afforded the title compound as a pale yellow solid.<sup>1</sup>H-NMR (400 MHz, DMSO-*d*<sub>6</sub>):  $\delta$ =14.02 (s, 1H), 10.06 (s, 1H), 8.91 (s, 1H), 8.14 (t, *J*=8.40 Hz, 2H), 7.87-7.87 (m, 3H), 7.46 (d, *J*=7.60 Hz, 1H), 7.31-7.32 (m, 3H) ppm.<sup>13</sup>C-NMR (100 MHz, DMSO-*d*<sub>6</sub>):  $\delta$ =13.98, 118.29, 118.95, 122.87, 123.59, 124.02, 124.36, 126.77, 126.97, 127.85, 128.04, 130.21, 130.57, 131.63, 132.49, 132.62, 134.54, 146.94, 152.82, 157.25, 159.01 ppm. MS. *m/z* =349.90 (M<sup>+</sup>).

#### 2-(anthracen-9-yl)-6-chloroquinoline-4-carboxylic acid (3j)

Elution from silica using 30% ethyl acetate in hexanes afforded the title compound as a pale brown solid.<sup>13</sup>C-NMR (100 MHz, DMSO-*d*<sub>6</sub>):  $\delta$ =13.72, 112.57, 113.45, 113.01, 116.32, 116.31, 117.64, 117.61, 117.34, 117.36, 117.67, 118.98, 118.91, 118.31, 118.32, 120.52, 120.31, 125.01, 127.01, 129.22, 135.96, 142.97, 159.48 ppm. MS. *m/z* =383.60 (M<sup>+</sup>).

### In silico molecular docking studies

The three dimensional structure of target protein Lactate dehydrogenase (PDB ID: 1CET) was downloaded from PDB [26] structural database. This file was then opened in SPDB viewer edited by removing the heteroatoms, adding C terminal oxygen. The active pockets on target protein molecule were found out using CAST pserver [27]. The ligands were drawn using Chem Draw Ultra 6.0


and assigned with proper 2D orientation (Chem Office package). 3D coordinates were prepared using PRODRG server [28]. Auto dock V3.0 was used to perform Automated Molecular Docking in AMD Athlon (TM)2x2 215 at 2.70 GHz, with 1.75 GB of RAM. Auto Dock 3.0 was compiled and run under Microsoft Windows XP service pack 3. For docking, grid map is required in Auto Dock, the size of the grid box was set at 72, 106 and 82 Å (R, G, and B), and grid center 25.714, 26.958, 9.32 for x, y, and z-coordinates. All torsions were allowed to rotate during docking. The Lamarckian genetic algorithm and the pseudo-Solis and Wets methods were applied for minimization, using default parameters [29].

## RESULT AND DISCUSSION


### Chemistry

The syntheses of the desired products are outlined in **scheme-1** by following standard literature procedures [30]. Thus, the 2-aryl/heteroaryl-6-chloroquinoline-4-carboxylic acids were prepared in which the condensation of 5-chloroisatin and

acetophenones/acylheterocyclic compounds in aqueous potassium hydroxide (33%) solution with EtOH solvent *via* Pfitzinger synthesis. Since our interest was to generate some biologically more important 2-aryl/heteroaryl-6-chloroquinoline-4-carboxylic acids, we employed normal Pfitzinger synthesis methodology with slight modification in their reaction, such that we could get good to excellent yield of the products (**3a-j**). Initially, we have reported the synthesis of 2-furyl-6-chloroquinoline-4-carboxylic acid **3a** by condensation of 5-chloroisatin and 2-acetylfuran in aqueous potassium hydroxide (33%) solution with EtOH solvent *via* Pfitzinger synthesis. Finally, by adopting optimized condition various 2-aryl/heteroaryl-quinoline-4-carboxylic acids were synthesized. By this reaction we could easily incorporate different aryl/heteroaryl rings at 2-position and a chloro at 6<sup>th</sup> position and a carboxylic group at 4<sup>th</sup> position simultaneously in one pot reaction. Thus antimalarial property through molecular docking studies with Lactate dehydrogenase (LDH) protein was assessed for all new ten ligands (**3a-j**).



**Scheme 1:** Pfitzinger synthesis of 2-aryl/heteroaryl-6-chloroquinoline-4-carboxylic acid derivatives (**3a-j**)
























### The structure of **3d** was elucidated as below

In <sup>1</sup>H-NMR spectrum four doublets at δ=8.25, 8.18, 7.77 and 7.88 ppm correspond to C<sub>12</sub>-H, C<sub>8</sub>-H, C<sub>7</sub>-H and C<sub>13</sub>-H protons. Singlet at δ=14.17 ppm corresponding to the acidic -COOH proton of quinoline, in addition two singlets at δ=8.77 and 8.54 ppm corresponds to C<sub>5</sub>-H and C<sub>3</sub>-H proton respectively. The other peaks have appeared in the expected region and the number of protons is in accordance with the expected structure. Additional support to elucidate the structure is obtained from <sup>13</sup>C-NMR

spectra of this compound. The appearance of peak at δ=166.90 ppm corresponds to the acidic -COOH carbon atom. The peaks at δ=120.24, 123.98, 124.3, 129.18, 129.19, 129.19, 130.73, 131.75, 131.90, 132.57, 136.56, 136.56, 146.82, 155.10 ppm corresponds to C<sub>14</sub>, C<sub>10</sub>, C<sub>3</sub>, C<sub>12</sub>, C<sub>16</sub>, C<sub>8</sub>, C<sub>7</sub>, C<sub>13</sub>, C<sub>15</sub>, C<sub>6</sub>, C<sub>11</sub>, C<sub>4</sub>, C<sub>9</sub> and C<sub>2</sub>. The mass spectrum of **3d** was recorded as additional evidence to the proposed structure and it exhibited M+1 peak at m/z 363.6. From all these spectral evidences the structure of **3d** has been confirmed. Similarly, structures of all other derivatives were established and presented in experimental section.

**Table 1: Physical data of 2-aryl/heteroaryl-6-chloroquinoline-4-carboxylic acid derivatives (3a-j)**

Entry	Acetophenones (2a-j)	Products (3a-j)	Yield (%)	M. P °C
3a			80	290-295
3b			78	285-290
3c			80	235-240
3d			75	270-275
3e			80	280-285
3f			78	300-305
3g			75	220-225
3h			80	310-315
3i			75	250-255
3j			75	315-320




**Fig. 3: Three dimensional structure of LDH protein PDBID: 1CET)**

### Molecular docking studies

The synthesized 2-aryl/heteroaryl-6-chloroquinoline-4-carboxylic acid derivatives (**3a-j**) were tested *in silico* to get the greatest conformer for their inhibitory properties against plasmodium LDH receptor protein (**Fig. 3**). The different bonds i. e. hydrogen bonds, van der Waals forces and hydrophobic behavior with amino acids were in good agreement with the predicted binding affinities obtained by molecular docking studies as verified by antimalarial studies where ligand 2-(4-bromophenyl)-6-chloroquinoline-4-carboxylic acid (**3d**) was the most active compared with standard drug Chloroquine (Table 2). Based on the molecular docking studies, the Plasmodium LDH protein is interacts with Chloroquine drug has two hydrogen bonds within active site amino acids HIS195 and ALA236 having binding energy -6.74 kcal/mol (**Fig.4**). The ligand 2-(4-bromophenyl)-6-chloroquinoline-4-carboxylic acid (**3d**) has five

hydrogen bonds with strong interactions within active site amino acids GLY29, GLY32, THR97, ILE31 and THR97 with binding energy of -9.05 kcal/mol. In the same way ligands **3b**, **3c**, **3g** and **3j** forms four hydrogen bonding interaction with amino acids THR97, ILE31, GLY32, GLY29, ARG171, VAL138, ARG171 and ASN140 having binding energy -8.73, -8.75, -9.88 and -7.98 kcal/mol respectively, indicates more potent inhibitors of Plasmodium LDH. However, the ligands **3e**, **3h**, **3i** shows three hydrogen bonding interaction with binding energy of -8.0, -9.02, and -8.44 kcal/mol respectively implies that these ligands have moderate interaction. Surprisingly, the ligand **3f** has shown no interaction with target protein and hence can't be considered as an inhibitor of Plasmodium LDH. Overall the docking of ligands **3a-j** except **3f** with LDH domain revealed that, our synthesized molecules which are having inhibitory capability are exhibiting interactions with one or the other amino acids in the active pockets as shown in (**Fig. 5**).



**Fig. 4: Docking image of chloroquine interact with LDH protein**

**Table 2: Molecular docking results of chloroquine and synthesized ligands 2-aryl/heteroaryl-6-chloroquinoline-4-carboxylic acid derivatives (3a-j) with plasmodium LDH receptor protein**

Ligands	Binding Energy (kcal/mol)	Docking energy	Inhibitory Constant ( $\mu\text{M}$ )	Intermol Energy (kcal/mol)	H- bonds	Bonding
3a	-7.81	-9.3	1.89e-006	-9.05	2	3a: :DRG: OAM: LD: A: ASN140:HD22 3a: :DRG: OAR: LD: A: VAL142:HN
3b	-8.73	-9.32	3.99e-007	-9.35	4	3b: :DRG: OAS: LD: A: THR97:HG1 3b: :DRG: OAT: LD: A: ILE31:HN 3b: :DRG: OAS: LD: A: GLY32:HN 3b: :DRG: OAS: LD: A: GLY29:HN
3c	-8.75	-9.32	3.85e-007	-9.37	4	3c: :DRG: OAU: LD: A: GLY29:HN 3c: :DRG: OAT: LD: A: GLY32:HN 3c: :DRG: OAU: LD: A: THR97:HG1 3c: :DRG: OAT: LD: A: ILE31:HN
<b>3d</b>	<b>-9.05</b>	-9.7	2.33 e-007	-9.67	<b>5</b>	3d: :DRG: OAU: LD: A: GLY29:HN 3d: :DRG: OAT: LD: A: GLY32:HN 3d: :DRG: OAU: LD: A: THR97:HG1 3d: :DRG: OAT: LD: A: ILE31:HN 3d: :DRG: NAI: LD: A: THR97:O
3e	-8.44	-9.56	6.46e-007	-9.38	3	3e: :DRG: OAU: LD: A: GLY32:HN 3e: :DRG: OAV: LD: A: ILE31:HN 3e: :DRG: NAJ: LD: A: THR97:O
3f	112	111.18	----	111.09	-	
3g	-7.98	-9.68	1.42 e-006	-9.54	4	3g: :DRG: OAZ: LD: A: RG171:HH11 3g: :DRG: OAQ: LD: A: VAL138:O 3g: :DRG: OAY: LD: A: RG171:HH21 3g: :DRG: OAR: LD: A: ASN140:OD1
3h	-8.0	-8.72	1.37e-006	-8.62	3	3h: :DRG: OAX: LD: A: ARG171:HH11 3h: :DRG: OAX: LD: A: ARG171:HH21 3h: :DRG: OAW: LD: A: HIS195:HE2
3i	-9.02	-9.66	2.44e-007	-9.64	3	3i: :DRG: OAX: LD: A: ARG171:HH21 3i: :DRG: OAY: LD: A: ARG171:HH11 3i: :DRG: HAW: LD: A: VAL138:O
3j	-9.88	-10.85	5.76e-008	-10.5	4	3j: :DRG: OBA: LD: A: THR97:HG1 3j: :DRG: OBB: LD: A: GLY32:HN 3j: :DRG: OAT: LD: A: ILE31:HN 3j: :DRG: OBA: LD: A: GLY29:HN
<b>Chloroquine</b>	-6.74	-8.43	1.15e-005	-9.23	2	STD: :DRG: HA5:LD: A: HIS195:O STD: :DRG: NAG: LD: A: ALA236:HN




Fig. 5: Docking images of compound 3d and 3j interaction with LDH protein shows five and four hydrogen bonds with binding energy -9.05 kcal/mol & -9.88 kcal/mol

## CONCLUSION

The convenient syntheses of new 2-aryl/heteroaryl-6-chloroquinoline-4-carboxylic acid derivatives (**3a-j**) were described via Pfitzinger reaction. The *in silico* molecular docking studies reveals that derivatives **3a-j** except **3f** were shown interaction with plasmodium LDH. In that the compound **3d** shows maximum of five hydrogen bonding interaction with binding energy -9.05 kcal/mol. Thus, this basic result would certainly draw attention from researcher to identify lead inhibitor of plasmodium LDH receptor protein.

## ACKNOWLEDGEMENT

The authors are thankful to IISc Bangalore and University of Mysore, Mysore for providing spectral data and the authorities of Kuvempu University for providing the necessary facilities to carry out the present work. One of the authors, T. O. Shrunghesh Kumar is thankful to SC/ST Cell Kuvempu University for the award of Senior Research Fellowship.

## CONFLICT OF INTERESTS

Declared None

## REFERENCES

- Akranth M, Tanwar OP, Rikta S, Mohammad RA, Sandeep S, Mymoona AMS, *et al.* Quinoline: a versatile heterocyclic. Saudi Pharm J 2013;2:1-12.
- Elliot JM, Carling RW, Chambers M, Chicchi GG, Hutson PH, Jones AB, *et al.* N',2-Diphenylquinoline-4-carbohydrazide based NK3 receptor antagonists. Bioorg Med Chem Lett 2006;22:5748-51.
- Kovi KE, Yearick K, Iwaniuk DP, Natarajan JK, Alumasa J. de Dois AC, *et al.* Synthesis and antimalarial activity of new 2-methyl-6-ureido-4-quinolinamides sulfonamides, ureas and thioureas. Bioorg Med Chem 2009;17:270-83.
- Kumar A, Srivastava K, Kumar SR, Puri SK, Chauhan PMS. Synthesis and bio evaluation of hybrid 4-aminoquinoline triazines as a new class of antimalarial agents. Bioorg Med Chem Lett 2008;18:6530-3.
- Chibale K, Moss JR, Blackie M, Schalkwyk D, Smith PJ. New amine and urea analogs of ferrochloroquine: synthesis, antimalarial activity *in vitro* and electrochemical studies. Tetrahedron Lett 2000;41:6231-5.
- Mahajan A, Yeh S, Nell M, Rensburg CEJ, Chibale K. Synthesis of new 7-chloroquinolinyl thioureas and their biological investigation as potential anti-malarial and anticancer agents. Bioorg Med Chem Lett 2007;17:5683-5.
- Horn J, Marsden SP, Nelson A, House D, Weingarten GG. Convergent, regiospecific synthesis of quinolines from o-aminophenylboronates. Org Lett 2008;10:4117-20.
- Liu XY, Ding P, Huang JS, Che CM. Synthesis of substituted 1,2-dihydroquinolines and quinolines from aromatic amines and alkynes by gold(I)-catalyzed tandem hydro amination-hydro arylation under microwave-assisted conditions. Org Lett 2007;9:2645-9.
- Fan J, Wan C, Sun G, Want ZJ. Cascade synthesis of 3-quinolinecarboxylic ester via benzylation/propargylation-cyclization. Org Chem 2008;73:8608-11.
- Tokunaga M, Eckert M, Wakatsuki Y. Ruthenium-catalyzed intermolecular hydroamination of terminal alkynes with anilines: A practical synthesis of aromatic ketamine. Angew Chem Int Ed 1999;38:3222-5.
- Jie-Jack Li: Name Reactions in Organic Chemistry. Wiley-Interscience; New York; 2005.
- Ahmad NM. Quinolines. In: Li JJ, Gribble GW, editors. Palladium in Heterocyclic Chemistry. 2<sup>nd</sup> ed. New York: Elsevier; 2007.
- Raynes K, Foley M, Tilley L, Deady LW. Novel bisquinoline antimalarials: synthesis, antimalarial activity and inhibition of haem polymerisation. Biochem Pharmacol 1996;52:551-9.
- KiranKumar HC, Mahadevan KM, Manjappa KB. High throughput one pot synthesis of 2-methylquinolines. Tetrahedron Lett 2013;54:1368-70.
- Bindu PJ, Mahadevan KM, Ravikumar Naik TR. An efficient one pot synthesis and photo-induced DNA cleavage studies of 2-chloro-3-(5-aryl-4,5-dihydroisoxazol-3-yl)quinolines. Bioorg Med Chem Lett 2012;22(19):6095-8.
- Bindu PJ, Mahadevan KM, Ravikumar Naik TR. Sm(III)nitrate-catalyzed one-pot synthesis of furano[3,2c]-1,2,3,4-tetrahydroquinolines and DNA photocleavage studies. J Mol Struct 2012;1020:142-7.
- KiranKumar HC, Mahadevan KM, Prabhakara VP, Srinivasa A. One pot Synthesis of medicinally important *cis*-2-Methyl-4-amino substituted-1,2,3,4-tetrahydroquinoline. Chin J Chem 2012;30:534-40.
- Bindu PJ, Mahadevan KM, Satyanarayan ND, Ravikumar Naik TR. Synthesis and DNA cleavage studies of novel quinoline oxime esters. Bioorg Med Chem Lett 2012;22:898-900.
- Prabhakara VP, Sherigara BS, Mahadevan KM, Vijaykumar H. Synthesis and DNA cleavage studies of novel quinoline oxime esters. Synth Commun 2010;40:2220-31.
- Srinivasa A, Mahadevan KM, Vijaykumar H. Imino Diels-Alder reactions: efficient synthesis of 2-Aryl-4-(2'-oxopyrrolidinyl-1')-1,2,3,4-tetrahydroquinolines catalyzed by antimony (III) Sulphate. Monatsh Chem 2008;139:255-9.
- Siddalingamurthy E, Mahadevan KM, Jagadeesh NM, Kumara MN. Synthesis and docking study of 3-(N-alkyl/aryl piperidyl) indoles with serotonin-5HT<sub>1</sub>H<sub>1</sub> and CCR2 receptors antagonist. Int J Pharm Pharm Sci 2014;6:475-82.
- Jagadeesh NM, Mahadevan KM, Kumara MN, Prashantha N. Synthesis and molecular docking study of N-alkyl/aryl-2-aryl indol-3-yl glyoxylamides as novel anticancer agents. Int J Pharm Pharm Sci 2014;6:921-6.
- Jagadeesh NM, Mahadevan KM, Preenon B. Synthesis, molecular docking and fluorescent properties of novel (*E*)-3-(9-ethyl-9*H*-carbazol-3yl)-1-phenylprop-2-en-1-ones. Int J Pharm Pharm Sci 2014;6(10):317-25.
- Siddalingamurthy E, Mahadevan KM, Jagadeesh NM, Kumara MN. Synthesis of novel  $\gamma$ -carboline derivatives and their *in*

- silico* studies on 5HT1, H1 and CCR2 antagonist receptors. *Int J Pharm Pharm Sci* 2014;6(10):548-54.
25. ShrungheshKumar TO, Mahadevan KM, Kumara MN. Synthesis and cytotoxic studies of 2, 3-dimethylindoles and tetrahydrocarbazoles. *Int J Pharm Pharm Sci* 2014;6(2):137-40.
  26. Binkowski TA, Naghibzadeg S, Liang J. CASTp computed atlas of surface topography of proteins. *Nucleic Acids Res* 2003;31:3352-5.
  27. Ghose AK, Crippen GM. Atomic physicochemical parameters for three dimensional-structure-directed quantitative structure-activity relationships. Modeling dispersive and hydrophobic interactions. *J Chem Inf Comput Sci* 1987;27:21-35.
  28. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ. Automated docking using a Lamarckian Genetic Algorithm and empirical binding free energy function. *J Comput Chem* 1998;19:1639-62.
  29. Pfitzinger W. Chinolinderivateauslsatinsäure. *J Prakt Chem* 1886;33:100.